Cryo-Save sets up Indian operations
This article was originally published in Scrip
Executive Summary
The Cryo-Save Group, Europe's largest adult stem cell storage bank, has launched operations in India. It has set up a wholly owned subsidiary, Cryo-Save India, with an investment of €1.8 million.This is expected to be scaled up to €2 million within a year of operation. Cryo-Save India is headquartered in Bangalore and has a fully automated adult stem cell storage facility with a storage capacity of 150,000 samples, extendable to 300,000 immediately. Cryo-Save processes samples automatically to avoid manual intervention and contamination. The company collects and stores adult stem cells derived from cord blood. The Cryo-Save Group, established in 2000, is headquartered in the Netherlands, and owns, or has access to, laboratory and storage facilities in Belgium, Germany and Dubai.
You may also be interested in...
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.
How Sanofi Is ‘Playing To Win’ In India, Watch Diabetes Space
Sanofi India managing director Rodolfo Hrosz talks to Scrip about the company’s refreshed India strategy including in the competitive diabetes segment, which is expected to see a flurry of new product activity. While Soliqua has hit the market, all eyes are also on Novo Nordisk’s Awiqli and Cipla’s partnered inhaled insulin in the wings.
Asia Deal Watch: Nippon Shinyaku Takes On Intractable Rare Disease With MiNA
Plus deals involving Incyte/CMS, Biocytogen/ABL, Bharat/Biofabri/Bilthoven, Dr. Reddy’s/Pharmazz, Veeda/Heads, Sosei Heptares/GSK, BioGeometry/Sanyou, Ono/Sibylla and Teijin/BioProjet